We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

166 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

12% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 58

20% less funds holding

Funds holding: 208166 (-42)

26% less call options, than puts

Call options by funds: $35.5M | Put options by funds: $48.1M

48% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 88

72% less capital invested

Capital invested by funds: $2.85B → $801M (-$2.05B)

Holders
166
Holders Change
-42
Holders Change %
-20.19%
% of All Funds
4.82%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
46
Increased
51
Reduced
58
Closed
88
Calls
$35.5M
Puts
$48.1M
Net Calls
-$12.6M
Net Calls Change
+$3.73M
Name Holding Trade Value Shares
Change
Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$1.97M -$2.09M -387,776 -57%
PI
52
Putnam Investments
Massachusetts
$1.92M +$1.52M +281,094 New
PRCM
53
Pine River Capital Management
Minnesota
$1.68M +$1.33M +246,700 New
U
54
UBS
Switzerland
$1.62M +$364K +67,389 +40%
NTCOC
55
Northern Trust Company of Connecticut
Connecticut
$1.49M -$6.01K -1,113 -0.5%
PCA
56
Private Capital Advisors
Connecticut
$1.43M +$1.13M +210,000 New
Zurich Cantonal Bank
57
Zurich Cantonal Bank
Switzerland
$1.36M +$297K +55,000 +38%
CNB
58
City National Bank
California
$1.32M +$835K +154,729 +392%
ECP
59
Elk Creek Partners
Colorado
$1.31M +$1.04M +191,965 New
Bank of America
60
Bank of America
North Carolina
$1.08M -$761K -141,016 -47%
Swiss National Bank
61
Swiss National Bank
Switzerland
$1.07M
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$1.07M +$795K +147,319 +1,639%
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$1.03M -$91.1K -16,873 -10%
SC
64
Skylands Capital
Wisconsin
$1.02M +$810K +150,000 New
CA
65
Commerzbank Aktiengesellschaft
Germany
$898K +$497K +91,993 +312%
State of Wisconsin Investment Board
66
State of Wisconsin Investment Board
Wisconsin
$894K -$25.7K -4,760 -4%
GTC
67
Ghost Tree Capital
New York
$887K +$702K +130,000 New
WMSA
68
Weiss Multi-Strategy Advisers
New York
$859K +$86.3K +15,980 +15%
BG
69
BlackRock Group
United Kingdom
$822K -$2.53M -468,130 -80%
PIM
70
Platinum Investment Management
Australia
$765K +$324K +60,000 +115%
Jane Street
71
Jane Street
New York
$749K +$593K +109,832 New
AllianceBernstein
72
AllianceBernstein
Tennessee
$701K -$971K -179,772 -64%
DekaBank Deutsche Girozentrale
73
DekaBank Deutsche Girozentrale
Germany
$691K +$12.4K +2,300 +2%
6CM
74
683 Capital Management
New York
$682K +$540K +100,000 New
VOYA Investment Management
75
VOYA Investment Management
Georgia
$662K

ARIA Hedge Fund Activity: Q4 2013 in Review

166 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2013, worth a combined $801M — down 72% from $2.85B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of ARIA and 46 opened new positions — a net loss of 42 holders — while 58 trimmed existing stakes and 51 added.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $106M sold.

  • 166 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2013, down from 208 in Q3 2013.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q4 2013, down 72% quarter-over-quarter.
  • 46 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2013 and 88 closed out, a net change of -42 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2013 was Camber Capital Management, an estimated $28.3M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2013 was Waddell & Reed Financial, an estimated $106M sold.

Based on aggregated 13F filings for Q4 2013.